Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.
Thrive Earlier Detection, a US-based cancer screening technology spinout of Johns Hopkins University, collected $257m yesterday in a series B round co-led by Casdin Capital and Section 32.
Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, also invested, as did Brown Advisory, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Spring Capital, Sands Capital and undisclosed investors including clients advised by T Rowe Price Associates.
Thrive Earlier Detection is commercialising a blood test called CancerSeek that detects multiple forms of the disease at early stages of progression by distinguishing biomarkers such as circulating tumour DNA – fragments from cancerous cells which roam freely in the patient’s bloodstream.
The hope is that CancerSeek could be combined with existing tests to diagnose most cancer subtypes effectively and in asymptomatic patients, enabling treatment before disease progression becomes severe.
